Therapy for Children With Advanced Stage High Risk Neuroblastoma

• Status: Completed
• Trial end date: 2001-04-01
• Target enrollment: 0
• Participant gender: All

Summary

This is a Phase II pilot study of chemotherapy and surgery for children with advanced stage high-risk neuroblastoma utilizing topotecan during an upfront window and other active agents during induction and intensification phases. The primary purpose is to estimate the response rate to an upfront window of two cycles of intravenous topotecan. We hypothesize that the topotecan window will be an effective therapy in terms of the response rate.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: St. Jude Children's Research Hospital
• Collaborator: National Institutes of Health (NIH)
• Treatments: Carboplatin; Cyclophosphamide; Doxorubicin; Etoposide; Ifosfamide; Topotecan

Criteria

Inclusion Criteria:

• Advanced stage,high-risk neuroblastoma

• Histologic proof of neuroblastoma

• Adequate renal function

• ECOG performance status 0-2

Exclusion Criteria:

• Previous therapy